₹884.0
-0.29% today
· 30d -9.29%
as of 2026-11-09
Price · Daily Candles
“Orchid Pharma battles declining profits as DII interest sparks, FIIs trim holdings.”
Orchid Pharma has experienced an annual net profit decline of 79.38% on a 12% revenue drop in the last fiscal year, pushing its TTM PE to a lofty 191.12. Despite this, DIIs increased their stake by 0.86% QoQ, offsetting FIIs' 0.3% reduction.
BULL CASE
+DIIs increased their stake by 0.86% QoQ in Q4 2026, reaching 20.25%.
+Quarterly net profit rose 6.66% YoY to ₹24 Cr in Q4 2026.
+Quarterly revenue grew by 0.05% YoY to ₹238 Cr in Q4 2026.
+The stock has shown significant short-term momentum, gaining 26.31% in the last month.
BEAR CASE
−Annual net profit plummeted 79.38% YoY to ₹21 Cr in FY26.
−Annual revenue decreased by 12.0% YoY to ₹811 Cr in FY26.
−The TTM PE ratio stands at 191.12, significantly higher than the forward PE of 22.57, suggesting current earnings are depressed.
−Promoter holding remains high at 69.84%, with no change QoQ.
−The company's FCF for the last 12 months is negative at -₹282 Cr.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹304 Cr
+75.89% YoY
NET PROFIT
₹3 Cr
-78.38% YoY
OPM
5.17%
-8.72pp YoY
EPS
₹0.54
PE 191.12
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-6.2% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Orchid Pharma's TTM PE of 191.12 significantly outpaces peers like SUNPHARMA (40.41) and DRREDDY (19.55), while its ROCE of 8.0% lags behind the likes of CIPLA (25.09) and ZYDUSLIFE (25.71).
PEERPEROCE %
ORCHPHARMA191.128.0
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
39
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
STRONG
75
Valuation
STRETCHED
5
Growth
DECLINING
21
Profitability
AVERAGE
45
Technicals
WEAK
40
Risk
MODERATE
50
Key Stats
TTM PE
191.12
P/B
2.9
52W HIGH
₹1143.5
OFF HIGH
-22.69%
MKT CAP
₹4536 Cr
◉ Active Signals
MACDNeutral7.2042
RSI(14)Neutral46.79
Street Consensus
3 analysts₹949.33
mean target
Low ₹900.0Now ₹884.0High ₹1003.0
⧉ Strategy Fit 🔒